ArticleHaematologica2020
Mutations associated with a 17-gene leukemia stem cell score and the score's prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia.
Open access · goldAbstract read
In one paragraph
Article in Haematologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 38 citations in OpenAlex.
- Co-option of lineage plasticity as a hallmark of multipotent acute leukemias.Blood neoplasia · 2026Review
- Diving into the transcriptional landscape of leukemic stem cells in acute myeloid leukemia at single-cell resolution.Journal of cancer research and clinical oncology · 2026Review
- The LSC17 score: a prognostic biomarker now validated for real-world clinical application in acute myeloid leukemia.Haematologica · 2026Article
- Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia.Haematologica · 2026Article
- The expression patterns and prognostic significance of PD-1 and TIM-3 on T cells and the differentiated subsets in acute myeloid leukemia.Annals of hematology · 2025Article
- Improving risk stratification for 2022 European LeukemiaNet favorable-risk patients with acute myeloid leukemia.Innovation (Cambridge (Mass.)) · 2024Article
- Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia.Nature genetics · 2024Article
- Identification of a Complex Karyotype Signature with Clinical Implications in AML and MDS-EB Using Gene Expression Profiling.Cancers · 2023Article
- LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study.Blood advances · 2023Article
- Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia.Cancer discovery · 2023Article
- Modern Risk Stratification of Acute Myeloid Leukemia in 2023: Integrating Established and Emerging Prognostic Factors.Cancers · 2023Review
- TP53-Mutated Myelodysplasia and Acute Myeloid Leukemia.Mediterranean journal of hematology and infectious diseases · 2023Review
- Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia.The Journal of clinical investigation · 2022Article
- Large-Scale In Vitro and In Vivo CRISPR-Cas9 Knockout Screens Identify a 16-Gene Fitness Score for Improved Risk Assessment in Acute Myeloid Leukemia.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Article
- Human acute myeloid leukemia stem cells: evolution of concept.Blood research · 2022Review
- Multimerin-1 and cancer: a review.Bioscience reports · 2022Review
- A clinical laboratory-developed LSC17 stemness score assay for rapid risk assessment of patients with acute myeloid leukemia.Blood advances · 2022Article
- Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers.Haematologica · 2022Review
- Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq.Leukemia · 2021Article
Corrections and comments
- Commented on by
Authors and funding
18 authors at 5 institutions in 1 country.
Marius BillThe Ohio State University Comprehensive Cancer Center, Columbus, OH marius.bill@osumc.edu.
Deedra NicoletThe Ohio State University Comprehensive Cancer Center, Columbus, OH.
Jessica KohlschmidtThe Ohio State University Comprehensive Cancer Center, Columbus, OH.
Christopher J WalkerThe Ohio State University Comprehensive Cancer Center, Columbus, OH.
Krzysztof MrózekThe Ohio State University Comprehensive Cancer Center, Columbus, OH.
Ann-Kathrin EisfeldThe Ohio State University Comprehensive Cancer Center, Columbus, OH.
Dimitrios PapaioannouThe Ohio State University Comprehensive Cancer Center, Columbus, OH.
Xiaoqing Rong-MullinsThe Ohio State University Comprehensive Cancer Center, Columbus, OH.
Zachary BrannanThe Ohio State University Comprehensive Cancer Center, Columbus, OH.
Jonathan E KolitzMonter Cancer Center, Hofstra Northwell School of Medicine, Lake Success, NY.
Bayard L PowellComprehensive Cancer Center of Wake Forest University, Winston-Salem, NC.
Kellie J ArcherThe Ohio State University Comprehensive Cancer Center, Columbus, OH.
Adrienne M DorranceThe Ohio State University Comprehensive Cancer Center, Columbus, OH.
Andrew J CarrollDepartment of Genetics, University of Alabama at Birmingham, Birmingham, AL.
Richard M StoneDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
John C ByrdThe Ohio State University Comprehensive Cancer Center, Columbus, OH.
Ramiro GarzonThe Ohio State University Comprehensive Cancer Center, Columbus, OH.
Clara D BloomfieldThe Ohio State University Comprehensive Cancer Center, Columbus, OH clara.bloomfield@osumc.edu.
The Ohio State University · USDana-Farber Cancer Institute · USHofstra University · USUniversity of Alabama at Birmingham · USWake Forest University · US
Funding
Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3MTranslational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3MStatistics CoreU10CA180882 · NCI · MAYO CLINIC ROCHESTER · PI Sumithra Jay Mandrekar · 2014 to 2026
$115.0MTHE ALLIANCE NCTN BIOREPOSITORY AND BIOSPECIMEN RESOURCEU24CA196171 · NCI · WASHINGTON UNIVERSITY · PI Mine Cicek, Wendy Frankel · 2015 to 2026
$35.0MSPORE Leukemia Tissue BankP50CA140158 · NCI · OHIO STATE UNIVERSITY · PI BLOOMFIELD, CLARA D · 2009 to 2013
$11.2MCancer and Leukemia Group B - Leukemia Correlative SciencesU10CA101140 · NCI · OHIO STATE UNIVERSITY · PI MARCUCCI, GUIDO · 2003 to 2013
$10.3MOSU as a Network Lead Academic Participating Site for the NCI NCTNUG1CA233331 · NCI · OHIO STATE UNIVERSITY · PI John L. Hays, Dwight H. Owen · 2019 to 2026
$8.9MNCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareUG1CA233180 · NCI · DANA-FARBER CANCER INST · PI Harold John Burstein · 2019 to 2026
$8.6MCOMMUNITY CLINICAL ONCOLOGY PROGRAMU10CA045450 · NCI · ST. JOSEPH'S HOSPITAL (ATLANTA) · PI SEAY, THOMAS E · 1987 to 2012
$7.6MNORTH SHORE UNIV COMMUNITY CLINICAL ONCOLOGY PROGRAMU10CA035279 · NCI · NORTH SHORE UNIVERSITY HOSPITAL · PI VINCIGUERRA, VINCENT P · 1985 to 2014
$7.3MOSU as Network Lead Academic Participating Site for the NCI NCTNU10CA180850 · NCI · OHIO STATE UNIVERSITY · PI BLUM, KRISTIE A, CHAKRAVARTI, ARNAB · 2014 to 2018
$6.8MTargeted Therapy for LeukemiaR35CA197734 · NCI · UNIVERSITY OF CINCINNATI · PI BYRD, JOHN C. · 2015 to 2021
$6.6MNCI NIH HHS P30 CA016058NCI NIH HHS P50 CA140158NCI NIH HHS R35 CA197734NCI NIH HHS U10 CA003927NCI NIH HHS U10 CA032291NCI NIH HHS U10 CA035279NCI NIH HHS U10 CA045450NCI NIH HHS U10 CA059518NCI NIH HHS U10 CA101140NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180850NCI NIH HHS U10 CA180861NCI NIH HHS U10 CA180866NCI NIH HHS U10 CA180867NCI NIH HHS U10 CA180882NCI NIH HHS U24 CA196171NCI NIH HHS UG1 CA233180NCI NIH HHS UG1 CA233331NCI NIH HHS UG1 CA233338
Abstract
Leukemia stem cells (LSC) are more resistant to standard chemotherapy and their persistence during remission can cause relapse, which is still one of the major clinical challenges in the treatment of acute myeloid leukemia (AML). A better understanding of the mutational patterns and the prognostic impact of molecular markers associated with stemness could lead to better clinical management and improve patients' outcomes. We applied a previously described 17-gene expression score comprising genes differently expressed between LSC and leukemic bulk blasts, for 934 adult patients with
Indexed as
Leukemia, Myeloid, AcuteAdultHumansMiddle AgedMutationPrognosisStem CellsTreatment Outcome
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.